The chemoresistance occurrence significantly hinders the clinical treatment of advanced cancers, frequently leading to treatment failure.
It was already known that tripartite motif protein 19 (TRIM19) enhances the chemosensitivity of human ovarian cancers.
However, it remained unknown whether TRIM19 functions in the cisplatin resistance of endometrial cancer.
